NCT02510677

Brief Summary

The prognosis of patients with heart failure has improved due to recent breakthrough in medical treatment and cardiac resynchronization devices. However, there is no paraclinical parameter to assess response to cardiac resynchronization therapy (CRT). This is a major issue since about a third of implanted patients will not be improved by CRT. CZT SPECT allows to perform myocardial perfusion imaging in less than 4 minutes and is able to study myocardial perfusion, viability, left ventricular function, but also ventricular asynchrony. Using low-dose dobutamine gated SPECT and CZT camera, we aimed to assess left ventricular dyssynchrony in viable segments in patients with heart failure eligible for CRT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Jun 2013

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

July 22, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 29, 2015

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

February 1, 2017

Status Verified

January 1, 2017

Enrollment Period

3.6 years

First QC Date

July 22, 2015

Last Update Submit

January 31, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • measures of dyssynchrony parameters

    The primary endpoint is reproducible quantitative measures of dyssynchrony parameters between two successive acquisitions basal (entropy, bandwidth, standard deviation phase histogram).

    baseline

Study Arms (1)

myocardial perfusion scintigraphy

OTHER

Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.

Other: myocardial perfusion scintigraphy

Interventions

myocardial perfusion scintigraphy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with heart failure on optimal medical therapy and targeted for cardiac resynchronization therapy according to current recommendations;
  • Age over 18 years
  • Clinically stable (without hospitalization for heart failure in the last month)
  • Sinus rhythm
  • Social security insurance
  • Signed consent form

You may not qualify if:

  • Recent history (less than 21 days) of acute coronary syndrome or unstable angina;
  • Recent history (less than 1 month) of acute heart failure;
  • Right bundle branch block;
  • Irregular heart rate;
  • Double-chamber cardiac pacemaker
  • Patients previously implanted with a single-chamber cardioverter-defibrillator must have at least 99 percent of unstimulated QRS.
  • Countraindication to dobutamine therapy;
  • Valvular heart disease, congenital heart disease, hypertrophic cardiomyopathy;
  • Significant Ventricular arrhythmias;
  • Hypertension (upper than 160/100 mmHg);
  • Pregnant, breastfeeding or guardianship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Médecine Nucléaire du CHU de Caen

Caen, 14000, France

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 22, 2015

First Posted

July 29, 2015

Study Start

June 1, 2013

Primary Completion

January 1, 2017

Study Completion

January 1, 2017

Last Updated

February 1, 2017

Record last verified: 2017-01

Locations